SLAS2020 Scientific Program Committee

Melanie Leveridge, B.Sc.
GlaxoSmithKline, UK

Andrew Napper, Ph.D.
Evotec, USA

Track Chair:
Andreas Luippold, Ph.D.
Boehringer Ingelheim, Germany

Associate Track Chair:
Martin Giera, Ph.D.
Leiden University Medical Center, Netherlands

Track Chair:
Joe McGivern, Ph.D.
Amgen, USA

Associate Track Chair:
Melissa Crisp, Ph.D.
Eli Lilly, USA

Track Chair:
Sam Michael, Ph.D.
NIH, USA

Associate Track Chair:
Helen Plant, B.Sc.
AstraZeneca, UK

Track Chair:
Rob Howes, Ph.D.
AstraZeneca

Associate Track Chair:
Jan Reichert, Ph.D.
The Antibody Society, USA

Track Chair:
Jason Ekert, Ph.D
GlaxoSmithKline, USA

Associate Track Chair:
Nancy Allbritton, Ph.D.
University of North Carolina, USA

Track Chair:
Margaret Scott, Ph.D.
Genentech, USA

Associate Track Chair:
Tim Wigle, Ph.D.
Ribon Therapeutics, USA

Track Chair:
Yohann Potier, Ph.D.
Voyager Therapeutics

Associate Track Chair:
Nicola Richmond, Ph.D.
GlaxoSmithKline, UK

Track Chair:
Amar Basu, Ph.D.
Wayne State University, USA

Associate Track Chair:
Elodie Sollier, Ph.D.
Benkei, France

Track Chair:
Andrew Alt, Ph.D.
University of Michigan, USA

Associate Track Chair:
Guy Breitenbucher, Ph.D.
University of California San Francisco, USA

Track Chair:
Kristen Brennand, Ph.D.
Mount Sinai School of Medicine, USA

Associate Track Chair:
John Joslin, Ph.D.
Genomics Institute of the Novartis Research Foundation, USA